OncRef
Skip to newsletter content
|
RCCAugust 2026
0:00 / 2:53
Renal Cell Carcinoma — Monthly Compass
Aug 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in renal cell carcinoma this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
renal cell carcinoma updates
Key Highlights
Key Highlights
  • Key Clinical Development Updates
    • FDA granted Handa Oncology tentative approval under 505(b)(2) for OMCAZIO (cabozantinib) alternate‑salt capsules with RCC monotherapy and nivolumab‑combination indications on the label, and the company is preparing for commercial availability pending final approval.
    • FDA awarded Breakthrough Therapy and Fast Track designations to Norroy Bioscience’s 68Ga‑NYM096, a CAIX‑targeted PET agent intended to characterize indeterminate renal masses and differentiate ccRCC from non‑ccRCC, with Phase 1 trials planned in the U.S. and China and Fast Track benefits including more frequent FDA interactions and potential rolling NDA review, while Pliant Therapeutics received Fast Track for PLN‑101095 plus pembrolizumab with an ongoing FORTIFY Phase 1b ccRCC cohort and eligibility for rolling NDA submission.
  • Important Clinical Trial Publications
    • In the RADICAL study, adding a radiopharmaceutical to standard therapy in metastatic RCC did not improve skeletal events, tempering expectations for broad adoption of radiopharmaceutical add‑ons.
  • Key Conference Updates
    • Across the GU Cancers US Focus Meeting and KCRS26, faculty emphasized operationalizing adjuvant immunotherapy through sessions on selection and toxicity management, and KCRS26 presented patient‑reported outcomes from LITESPARK‑022.
    • KCRS26 spotlighted PD‑1×VEGF bispecifics (ivonescimab; PF‑08634404/SSGJ‑707) and next‑generation HIF‑2α inhibitors (belzutifan; casdatifan/ARC‑20), with RCC‑specific trials opening such as the Phase II IVORY study of ivonescimab.
  • Emerging Themes & Macro-Trends
    • Adjuvant dual‑pathway strategies combining PD‑1 and HIF‑2α inhibition are gaining momentum to reduce post‑nephrectomy relapse risk and may pressure current IO+TKI backbones pending mature outcomes.
    • Strategic focus is shifting toward biomarker infrastructure and access—KIM‑1 and PSMA imaging for selection and trial referral—and toward radiotherapeutics advancing in biomarker‑selected niches (e.g., PSMA‑positive ccRCC, oligometastatic cohorts) rather than unselected RCC populations.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-08-01 and 2026-08-31 about renal cell carcinoma.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Handa Pharmaceuticals (Handa Oncology) announced FDA tentative approval under the 505(b)(2) pathway for OMCAZIO (cabozantinib) capsules, an alternate-salt formulation. The label includes renal cell carcinoma indications (monotherapy and with nivolumab), and the company is preparing for commercial availability pending final approval. (handapharma.com) ¹ (read more)
  • Norroy Bioscience reported FDA Breakthrough Therapy and Fast Track designations for 68Ga‑NYM096, a CAIX‑targeted PET agent intended to characterize indeterminate renal masses and differentiate clear cell renal cell carcinoma from non‑ccRCC. The company plans to initiate phase 1 trials in the U.S. and China and noted Fast Track benefits including more frequent FDA interactions and potential rolling NDA review. (prnewswire.com) ² (read more)
  • Pliant Therapeutics received FDA Fast Track designation for PLN‑101095 plus pembrolizumab for ICI‑refractory advanced/metastatic solid tumors; the ongoing FORTIFY Phase 1b expansion includes a clear cell renal cell carcinoma cohort. Fast Track enables enhanced FDA engagement and rolling NDA submission eligibility as the program advances. (rss.globenewswire.com) ³ (read more)
  • OncLive covered the dual FDA designations for 68Ga‑NYM096 for ccRCC imaging, citing preliminary data and the developer’s plans to advance the program. The report reiterates that the designations aim to facilitate development and review for this PET radiopharmaceutical. (onclive.com) ⁴ (read more)
Conference
Major Conference Updates
Conference Information
  • GU Cancers US Focus Meeting 2026, Hyatt Regency Boston Harbor, Boston, MA; August 14–15, 2026. KCRS26 (Kidney Cancer Research Summit), InterContinental Boston, Boston, MA; July 23–24, 2026 (program published August 2026).
  • Overall takeaway: August content emphasized consolidation of adjuvant strategies, emergence of PD‑1/VEGF bispecifics and next‑gen HIF‑2α inhibitors as new backbones, and a cautious but persistent exploration of radiotherapeutics in RCC. (read more)
  • Theme 1: Adjuvant Intensification And Optimization
    • Significance: Persistent focus on reducing post‑nephrectomy relapse risk and operationalizing adjuvant IO in practice. KCRS26 featured patient‑reported outcomes from LITESPARK‑022, while GU Focus devoted sessions to adjuvant selection and management. (read more)
    • Mechanism insights / clinical impact: Dual‑pathway adjuvant approaches (PD‑1 plus HIF‑2α inhibition) aim to pair immune activation with hypoxia pathway blockade; concurrent toxicity management content (IO/VEGF/HIF inhibitors) signals real‑world readiness. (read more)
    • Patient populations affected: Resected ccRCC at increased risk of recurrence (including M1 NED); global relevance with emphasis on U.S. practice implementation. (read more)
  • Theme 2: Next‑Gen Backbones—PD‑1/VEGF Bispecifics And HIF‑2α Inhibitors
    • Significance: Movement beyond traditional IO+TKI doublets toward single‑molecule or dual‑backbone strategies that could streamline care and enable novel combinations. (read more)
    • Mechanism insights / clinical impact: Bispecifics targeting PD‑1×VEGF (ivonescimab; PF‑08634404/SSGJ‑707) and oral HIF‑2α inhibition (belzutifan; casdatifan/ARC‑20) featured across KCRS26 sessions and TIPS, with new RCC‑specific trials opening (ivonescimab Phase II IVORY). Corporate updates highlighted expansion into phase 3 HIF‑2α–anchored combinations. (read more)
    • Patient populations affected: Previously treated and refractory ccRCC; adjuvant failures; first‑line metastatic settings contemplated in development roadmaps. (read more)
  • Theme 3: Radiotherapeutics And Radiation‑Immune Interplay
    • Significance: Mixed signals but sustained interest; negative skeletal‑event endpoint in RADICAL tempers expectations, yet programs like LASER (177Lu‑PSMA‑617) and SBRT‑immunologic interplay continue to probe niches. (read more)
    • Mechanism insights / clinical impact: Alpha/beta‑emitting radiopharmaceuticals (radium‑223; 177Lu‑PSMA‑617) and SBRT may modulate tumor microenvironment and immunity; current data argue for biomarker‑guided deployment rather than broad adoption. (read more)
    • Patient populations affected: mRCC with bone metastases; PSMA‑positive ccRCC subsets; oligometastatic cohorts considered for SBRT‑IO combinations. (read more)
  • Theme 4: Cell Therapy And Engineered Payloads (Early Signals)
    • Significance: KCRS26 spotlighted engineered modalities (e.g., anti‑CAIX/CD70 DFIR CAR‑T secreting anti‑PD‑1/CTLA‑4 payload) as potential options post‑IO/TKI. (read more)
    • Mechanism insights / clinical impact: Local delivery of checkpoint molecules from CAR‑T constructs may overcome T‑cell exhaustion and cold tumor niches; still preclinical/early‑phase. (read more)
    • Patient populations affected: Heavily pretreated ccRCC with limited options; academic centers leading access. (read more)
  • Significance
    • Expected clinical or translational readouts: Progress from ivonescimab (IVORY) and PD‑1×VEGF programs; expanding HIF‑2α combinations (e.g., LITESPARK‑034) to define next‑line standards. (NCT06940518?utm_source=openai" style="color: #2563eb; text-decoration:none; font-weight:600;">trialant.com) (read more)
    • Regulatory or policy implications: None new in August; community education on toxicity management suggests payer and pathway alignment efforts are underway. (read more)
    • Potential shifts in standard of care: Adjuvant dual‑pathway strategies and PD‑1×VEGF/HIF‑2α backbones could pressure current IO+TKI pairings pending mature outcomes. (read more)
    • Strategic implications: Invest in biomarker infrastructure (e.g., KIM‑1, PSMA imaging) and trial access for bispecifics/HIF‑2α combinations; radiotherapeutics likely to advance in biomarker‑selected niches rather than broad RCC populations. (read more)
Publications Related to Approved Drugs
Phase 3
cabozantinib
Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER. A post-hoc analysis of the CheckMate 9ER trial revealed that the superior clinical outcomes with first-line nivolumab plus cabozantinib, compared to sunitinib, in advanced renal cell carcinoma are also associated with significant improvements in health-related quality of life. The data highlights that key symptom improvements, particularly reduced fatigue, are the primary drivers of this enhanced patient-reported well-being, reinforcing the combination's value proposition beyond efficacy alone. ()
New Publications Related to Drugs in Clinical Trial Development
Phase 2
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). The addition of Radium-223 to cabozantinib failed to improve symptomatic skeletal event-free survival (SSE-FS) in patients with metastatic renal cell carcinoma (mRCC) and bone metastases. The RADICAL trial was closed for futility, indicating this combination is not a viable strategy for this patient population despite a manageable safety profile. () .
Phase 3
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. In the LITESPARK-011 study, the combination of belzutifan and lenvatinib significantly extended progression-free survival compared to cabozantinib for patients with advanced clear-cell RCC who had progressed after anti-PD-1/L1 therapy. This positions the belzutifan-lenvatinib combination as a potential new standard of care in this treatment setting, pending overall survival data. () .
Phase 4
The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors. The phase 4 ITALIC-RCC trial is designed to determine if local ablation of the primary tumor, via deferred cytoreductive nephrectomy or SBRT, improves overall survival in mRCC patients who have already benefited from first-line anti-PD-1-based therapy. This study will address the critical, unresolved question of the role of local treatment in the modern immunotherapy era. () .
Phase 1
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer. The novel HIF-2α inhibitor casdatifan demonstrated significant and durable antitumour activity as a monotherapy in heavily pretreated patients with metastatic clear cell RCC. Clinical responses were strongly correlated with on-target biological activity, such as reductions in serum erythropoietin, establishing a clear link between HIF-2α pathway modulation and clinical efficacy. () .
Phase 1
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial. The off-the-shelf, allogeneic CAR T-cell therapy ALLO-316 demonstrated a manageable safety profile and promising antitumor activity in patients with advanced, heavily pretreated clear cell RCC. These findings from the TRAVERSE trial provide crucial proof-of-concept for allogeneic CAR T-cell therapy in solid tumors, especially for patients with high CD70 expression. () .
Phase 3
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study. After a median follow-up of nearly six years, adjuvant pembrolizumab continues to show a sustained and statistically significant benefit in both disease-free survival and overall survival for patients with clear cell RCC at high risk of recurrence post-nephrectomy. These long-term data reinforce adjuvant pembrolizumab as the established standard of care in this setting. () .
Phase 2
KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma. This exploratory analysis from the CALYPSO trial supports the utility of circulating Kidney Injury Molecule-1 (KIM-1) as a biomarker in advanced RCC. High baseline KIM-1 levels were associated with shorter overall survival in clear cell RCC, and dynamic changes during therapy correlated with outcomes, suggesting KIM-1 could serve as a valuable prognostic and monitoring tool. () .
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in renal cell carcinoma updated from 2026-08-01 to 2026-08-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation----1-1
Not Yet Recruiting3-2---5
Recruiting16141311146
Available-------
Approved for Marketing-------
Active, Not Recruiting5210-5-22
Completed--2---2
Total24162717176
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
No phase 1 trials completing within the next three months.
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Ipilimumab/ Nivolumab NCT04090710 COMPLETED Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer 2026-06-30
Ixazomib, Doxorubicin Hydrochloride, Gemcitabine, Doxorubicin, Ixazomib Citrate, Gemcitabine Hydrochloride NCT03587662 COMPLETED Phase II Trial of Ixazomib Combined With Gemcitabine and Doxorubicin in Patients With Renal Medullary Carcinoma 2026-08-04
Nivolumab, Evolocumab NCT06284564 ACTIVE_NOT_RECRUITING A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) 2026-10-01
Axitinib, Pembrolizumab, Tobemstomig, Tiragolumab NCT05805501 ACTIVE_NOT_RECRUITING A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma 2026-10-08
Axitinib, : Nivolumab NCT03595124 ACTIVE_NOT_RECRUITING A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups 2026-11-13
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
No phase 3 trials completing within the next three months.
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.